124 results about "Therapeutic action" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses a frontalon tooth healing targeting nano preparation and a preparation process thereof, belongs to the technical field of nano medicines, and aims to solve the problems that the natural regeneration capacity of teeth is limited and the combination of ethnic drugs and modern biotechnology is caused due to the lack of a targeting inhibition means for USAG-1. Comprising an anti-USAG-1 monoclonal antibody, ethnic drug components and a nano-carrier, the anti-USAG-1 monoclonal antibody is connected to the surface of the nano-carrier through covalent bonds, the ethnic drug components are loaded in the nano-carrier through physical action, and the nano-carrier is a polylactic acid-glycolic acid copolymer or chitosan; the anti-USAG-1 monoclonal antibody is used as a targeting ligand, is high in targeting property, can accurately reach a tooth focus, improves the drug utilization rate, enhances the curative effect, integrates multiple ethnic drug components, exerts a synergistic effect, can increase the contact area between the ethnic drug components and a biological membrane, promotes the absorption and transport of the drug, and improves the bioavailability of the drug. And the medicine can better play a treatment role.

The invention belongs to the technical field of biological medicine manufacturing, and particularly provides a preparation method of an engineered exosome capable of loading mitochondria for treating pulmonary fibrosis and the engineered exosome. The method comprises the following steps: constructing fusion plasmids for expressing mitochondrial targeting peptide fragment-therapeutic protein genes, dissolving the fusion plasmids in non-enzyme ultrapure water, adding the fusion plasmids into a lipid nano-preparation, and fully mixing to obtain a nano-preparation containing the therapeutic protein genes; the nano preparation is delivered into alveolar epithelial cells and is efficiently transfected, so that the homeostatic balance of the injured alveolar epithelial cells in the development of pulmonary fibrosis is effectively regulated and controlled, the secretion of an exosome with a therapeutic effect is promoted, and the engineered exosome is further obtained through mannose modification. The exosome can effectively load mitochondria and sequentially and accurately target macrophage mitochondria on the basis of a mannose target head and a mitochondrial targeting peptide fragment, so that macrophage mitochondrial homeostatic balance is effectively regulated and controlled, the purpose of reverse treatment of pulmonary fibrosis is achieved, and the exosome has high clinical application value.

The application provides a preparation of a sema7A monoclonal antibody 8A12 and a treatment effect of the sema7A monoclonal antibody 8A12 on lupus nephritis, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 8A12 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein, can effectively inhibit the macrophage inflammatory response induced by Sema7A, and can continuously and effectively reduce serum anti-double-stranded DNA antibodies and kidney damage of lupus mice. The monoclonal antibody 8A12 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus and / or lupus nephritis thereof.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The present invention provides a flow cytometer-based kit for detecting PD-1 in tumor patients. The kit, through antibody reagents containing PD-1-PE and Anti-IgG4-PE, can not only detect the PD-1 expression level in tumor patients, but also detect the PD-1 expression level in tumor patients who have been injected with anti-PD-1 monoclonal antibodies, providing better guidance for clinical medication and therapeutic effects. By adding a blocking agent to the diluent, a one-step incubation method is implemented for detection, shortening the detection time and improving the detection efficiency. At the same time, the Anti-IgG4-PE in the antibody reagent and the blocking agent and antioxidant in the diluent are optimized to improve the specificity and stability of the detection, thereby improving the accuracy of the detection. Using this kit for PD-1 detection has the advantages of simple operation, fast and convenient detection process, and accurate test results.

The invention discloses an application of chloroquine in preparation of a medicine for treating glutamine deficiency type tumors, the chloroquine promotes IFN-gamma signal transduction by up-regulating IFNGR1 protein expression, so that the therapeutic effect of immunotherapy on the glutamine deficiency type tumors, ASCT2 low expression tumors or autophagy-lysosomal pathway active tumors is enhanced. The invention provides a new thought and an effective means for solving the problem of immunotherapy drug resistance caused by glutamine metabolism limitation, and has important theoretical significance and potential clinical application value.

The invention discloses a nucleotide for inhibiting expression of ILKAP (Interleukin-7-Kinase Associated Protein) related circular RNA (Ribonucleic Acid) and application of the nucleotide, and the nucleotide is characterized in that the nucleotide sequence is CGUCAGUACUCGGGUUUCA, and the expression level of hsacirc0001116 can be specifically and obviously reduced. Experimental results prove that the nucleic acid molecule can effectively interfere with the expression of hsacirc0001116 in human non-small cell lung cancer A549 cells, and can significantly inhibit the survival of lung cancer cells. In addition, when the nucleic acid molecule is combined with an existing antitumor drug for use, a synergistic treatment effect can be generated.

The application discloses a kind of preparation and application of multi-target small nucleic acid drug based on small activation RNA technology, and is related to the field of biotechnology.The preparation method of the multi-target small nucleic acid drug includes the following steps: (1) selecting at least two anti-disease genes according to target disease;(2) intercepting the sequence of 1000 base pairs of the promoter region upstream of the coding region of the anti-disease gene;(3) according to the promoter sequence, avoid CpG island and locate the segment of species conservation, and cut a sequence containing 19 base length as a sense strand;(4) design an antisense strand according to the sense strand, and the 19 base of the antisense strand and the sense strand are completely complementary;(5) add two deoxythymine or uracil to the 3' end of each chain.The multi-target small nucleic acid drug has good therapeutic effect on heart failure, and has strong cancer cell killing ability and inhibition ability of cancer cell migration, and has wide application prospect.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

An antibody-conjugated liposome, particularly a nanoparticle. The surface of the nanoparticle contains antibodies. The number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, for example, a liposome, can more effectively exert a therapeutic effect on tumor and improve multidrug resistance of tumor, thereby overcoming the technical prejudice that it is commonly considered that the more antibodies on a surface of a liposome, the better the target cell binding effect, and laying a foundation for further clinical development.An antibody-conjugated liposome, particularly a nanoparticle, the surface of which contains antibodies, and the number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, such as a liposome, can more effectively exert a therapeutic effect on tumors and reduce the multidrug resistance of tumors. This overcomes the generally accepted technical bias that more antibodies on the surface of a liposome lead to better binding with target cells, thereby laying the foundation for further clinical development.

The application discloses application of a miR-8069 inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-8069 in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-8069 can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a model of cerebral stroke in vitro in research. The miR-8069 inhibitor disclosed by the application is used for preparing a medicine for treating cerebral stroke, and the nucleotide sequence is as follows: ACCGCCGACCGCCCCCAACCAUCC.

The invention discloses application of a miR-3960 inhibitor, and belongs to the technical field of biological medicines. The invention aims to find and discover miRNA markers related to AD diagnosis and treatment. Researches on AD pathogenesis discover that expression of the miR-3960 is significantly increased in AD patients, and further cell experiments discover that inhibition of the expression of the miR-3960 significantly improves the influence of A beta1-42 on cell viability, apoptosis, ROS and APP proteins, and the miR-3960 has a significant therapeutic effect on AD. A beta1-42 is a core component of amyloid plaque in the brain of an AD patient, and is widely applied to construction of AD cell models and animal models so as to research pathogenesis and drug evaluation of AD. The miR-3960 inhibitor is used for preparing a medicine for treating the Alzheimer's disease, and the nucleotide sequence of the miR-3960 inhibitor is CCCCCGCCUCCGCCGCCGCC.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

The invention relates to the technical field of medicines, in particular to application of a neuropeptide Y1 receptor antagonist in preparation of a hereditary polycystic kidney disease treatment medicine. The neuropeptide Y1 receptor antagonist is selected from a compound BIBO3304 which plays a role in blocking combination of neuropeptide Y (NPY) and a Y1 receptor subtype thereof. On the basis that early-stage histopathology, high-throughput sequencing, cytobiology and molecular biology are combined with in-vitro cell culture and in-vivo animal experiments, the potential treatment effect of the neuropeptide Y1 receptor antagonist in preparation of hereditary polycystic kidney disease treatment drugs is provided, and a new basis is provided for hereditary polycystic kidney disease treatment.

The invention belongs to the technical field of medicine, and discloses application of SHLP2 in preparation of medicine for relieving and treating acute and chronic inflammatory pain, and the amino acid sequence of SHLP2 polypeptide is MGVKFFTLSTRFFPSVQRAVPLWTNS. After the SHLP2 polypeptide is treated in an intrathecal (5 [mu] g / 10 [mu] g / 20 [mu] g) injection mode, the SHLP2 polypeptide shows a good treatment effect in an acute inflammation pain model induced by formalin and capsaicin and a chronic inflammation pain model induced by carrageenan and a complete Freund's adjuvant. The SHLP2 is utilized to target a mitochondrial genome, the effect of relieving acute and chronic inflammatory pain is achieved in a central sheath injection mode, and a target different from a traditional analgesic drug can be searched for treatment of the acute and chronic inflammatory pain.

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

The application discloses an application of a miR-4680-3p inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-4680-3p in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-4680-3p can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a classic model of cerebral apoplexy in vitro in research. The miR-4680-3p inhibitor disclosed by the application is used for preparing a medicine for treating ischemic apoplexy, and the nucleotide sequence of the miR-4680-3p inhibitor is as follows: UAACAACUCUUACAAUUCAGA.

Provided herein are compositions of chimeric shuttle-binder-effector fusion proteins with components related to modulating endogenous cytotoxic effector mechanisms, which are useful for therapeutic effects on predetermined target molecules. These shuttle-binder-effector proteins also have specific epitope binding affinities for these target molecules. Compositions for modified cells expressing these chimeric shuttle-binder-effector fusion proteins are also provided. Methods for the modification of cells to express these chimeric shuttle-binder-effector fusion proteins and for delivering the chimeric shuttle-binder-effector fusion proteins into target cells using the lytic granule cellular mechanisms in these modified cells are also provided.

The invention discloses a Toll-like receptor (TLR) agonist / organic photosensitizer protein nano-composite as well as a preparation method and application of the Toll-like receptor (TLR) agonist / organic photosensitizer protein nano-composite. In order to overcome the defects of short blood half-life period, low bioavailability and the like of the existing TLR agonist, the protein nano-composite is obtained by forming a compound in a protein cavity by using the TLR agonist and an organic photosensitizer, and has tumor and lymph node dual-targeting characteristics. The protein nano-composite is simple in preparation method, mild in condition, free of an organic solvent, uniform in particle size and has a pH-responsive drug release behavior, and the protein nano-composite is prepared by a one-step method with water as a solvent. Based on an active targeting mechanism mediated by an albumin binding receptor and an active uptake mechanism of antigen presenting cells to albumin, the nano-composite has tumor and lymph node dual-targeting characteristics, has immunotherapy and light therapy effects under irradiation of near-infrared light, and has a good application prospect from two aspects of short-term quick action and long-term body immunity improvement. Tumor growth is effectively restrained, and tumors are expected to be radically treated.

The application discloses an anti-RAGE antibody, which can target RAGE antigen targets of different species such as human, murine and monkey. The application further discloses a conjugate, a bispecific antibody, a multispecific antibody, an immune cell, and a fusion protein which respectively comprises the anti-RAGE antibody, and further discloses a method for displaying the anti-RAGE antibody on extracellular vesicles. The anti-RAGE antibody provided by the application is applied to display on extracellular vesicles, endowing the extracellular vesicles with targeting ability, and finally enriching the extracellular vesicles in specific lesion tissues or organs with high expression of RAGE antigens, thereby facilitating the delivery, release and therapeutic effects of other drug molecules loaded on the extracellular vesicles in the specific lesion tissues.

The invention provides an application of an ethyl acetate extract of angelica keiskei in preparation of a medicine for treating or preventing HCMV (human cytomegalovirus) infection. A preparation method of the angelica keiskei ethyl acetate extract comprises the following steps: taking fresh angelica keiskei medicinal material, air-drying, grinding into coarse powder, soaking with ethanol for 48 hours, percolating and extracting, collecting percolate, concentrating under reduced pressure until no ethanol smell exists, dispersing the obtained alcohol extract with warm water, adding isopyknic ethyl acetate for extraction, concentrating under reduced pressure until no ethyl acetate smell exists, and drying to obtain the angelica keiskei ethyl acetate extract. The angelica keiskei ethyl acetate extract is named as EEAK. According to the present invention, the research results show that the angelica keiskei ethyl acetate extract EEAK provides significant inhibition effects for the DNA copy numbers of the immediate early-stage protein IE1 / 2, the early-stage protein p52, the immediate early-stage gene UL123, the early-stage gene UL44 and the later-stage gene UL32 of the HCMV, provides significant prevention and treatment effects for the HCMV, has characteristics of low toxic-side effect, safety, effectiveness and good application prospects, and can be used for the HCMV infection.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The invention relates to an anti-S100A8 / A9 monoclonal antibody for treating severe acute pancreatitis and application of the anti-S100A8 / A9 monoclonal antibody. Specifically, the invention provides a nano antibody combined with dimers of S100A8 and S100A9 or an antigen binding fragment of the nano antibody, and provides application of the nano antibody or the antigen binding fragment in treatment of pancreatitis. Meanwhile, the invention also provides an application of the antibody combined with the dimers of the S100A8 and the S100A9 or the antigen binding fragment of the antibody in treatment of pancreatitis. The antibody provided by the invention has a good treatment effect on severe acute pancreatitis, and has important clinical significance and development value.

The invention relates to a synthesis method of alkaloid, and discloses a synthesis method of alkaloid (-)-psychotriadine and analogues thereof, and the synthesis method comprises the following steps: taking a tryptamine derivative as an initial raw material, taking an asymmetric Meerwein-Eschenmoser-Claisen rearrangement reaction and a Fischer indolation and Plancher rearrangement reaction as key reactions, and realizing the preparation of (-)-psychotriadine through a nine-step linear synthesis route. The method disclosed by the invention has gram-level amplification capability, and the problem of medicine source bottleneck of a natural sample and homologues thereof in future medicine research can be solved; meanwhile, it is verified through a Luciferase reporter gene experiment that (-)-psychotriadine and tetrahydropsychotriadine have the transcriptional activation activity of LXR [alpha] and LXR [beta], and the (-)-psychotriadine and the tetrahydropsychotriadine show the potential treatment effect on the Alzheimer's disease.

The present invention relates to a composition comprising HAPLN1 as an active ingredient for preventing or treating senile degenerative brain diseases. Specifically, recombinant human HAPLN1 protein (rhHAPLN1) lowers the protein level of p16 in cultured human astrocytes to inhibit cellular senescence caused by the accumulation of beta amyloid peptides, and further inhibits phosphorylation (p-p38 MAPK) of p38 MAPK protein, thereby also having the possibility of inhibiting inflammatory responses associated with the onset of Alzheimer's disease and Parkinson's disease. In addition, the recombinant human HAPLN1 protein (rhHAPLN1) exhibits significant memory and learning improvement effects in in vivo experiments performed using a mouse acute Alzheimer's disease model, and thus can be expected to exhibit preventive and therapeutic effects against Alzheimer's disease that may occur with aging and the like. In addition, the inhibitory effect of the rhHAPLN1 protein on cellular senescence and inflammatory responses of astrocytes can provide a very important clue for establishing prevention and treatment strategies not only for aging itself but also for brain functions, motor behaviors, memory, seizures, dementia, brain tumors, and the like.

The invention relates to application of orlistat in serving as or preparing a medicine for treating chlamydia infection, and belongs to the technical field of new application of medicines. The invention proposes that orlistat has a good treatment effect on genital tract infection caused by chlamydia trachomatis for the first time. In-vitro experiments and in-vivo experiments show that orlistat has a good effect of treating chlamydia genital tract infection. In addition, through conjoint analysis of transcriptomics and morphological results, key genes are screened out. The invention aims to clarify the effect of orlistat in treatment of genital tract Ct infection, further explore the specific mechanism of orlistat in inhibition of Ct growth and development, reveal the important role of part of chlamydia protein in Ct growth and development, and provide direction and possibility for promoting development of novel anti-Ct drugs.

The invention relates to the technical field of biological medicine, in particular to functionalized lipopeptide and a preparation method thereof, a functionalized lipopeptide-assisted nucleic acid drug lipid nano delivery system and application thereof. The functionalized lipopeptide is a compound formed by functionalized polyethylene glycol-lipid and partially or completely exposed amino groups of the functionalized hybrid polypeptide through a click chemical reaction or a Michael addition reaction; the functionalized hybrid polypeptide is a compound formed by an esterification reaction of an N-hydroxysuccinimide-polyethylene glycol-group and partially or completely exposed amino groups of the functionalized polypeptide. The lipopeptide provided by the invention is simple in preparation process and low in toxicity, and the lipopeptide-assisted nucleic acid drug lipid nano delivery system can realize high-efficiency delivery of various nucleic acid molecules such as siRNA, mRNA and DNA in vitro and in vivo and has a treatment effect on various diseases.

The present application relates to the technical field of RPS4X, and particularly relates to siRNA targeting RPS4X gene, LAMB3-PI3K-AKT signal pathway inhibitor, ovarian cancer drug and application. The siRNA targets and interferes with RPS4X gene expression. The siRNA and the LAMB3-PI3K-AKT signal pathway inhibitor are used on in-vitro ovarian cancer cells and in-vivo ovarian cancer tissues, and both have the effect of inhibiting proliferation, migration and invasion. The various siRNAs targeting RPS4X gene and the LAMB3-PI3K-AKT signal pathway inhibitors provided in the embodiments have the effects of promoting apoptosis of ovarian cancer cells and tissues and inhibiting tumor angiogenesis, have obvious ovarian cancer prevention and treatment effects, and have the application prospect of developing as ovarian cancer drugs.

The invention relates to the technical field of biological medicines, in particular to mRNA (messenger Ribonucleic Acid) for coding a single-chain antibody resisting staphylococcus aureus and application of the mRNA. On the basis of a specific scFv with high affinity to staphylococcus aureus lysate, cell wall protein and toxin, the mRNA is optimized by a gene sequence and is matched with a functional element suitable for in-vivo expression of the mRNA, so that stable and efficient expression of the mRNA in a target tissue is ensured. The mRNA is further prepared into an mRNA-LNP preparation, and the preparation is beneficial to delivery of the mRNA to local tissues of the mammary gland of the dairy cow, expresses scFv protein with a specific antibacterial function in epithelial cells of the mammary gland, can be used for replacing traditional antibiotics to treat the mastitis of the dairy cow caused by staphylococcus aureus, and has an outstanding treatment effect.